Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes

Diabetes Care

Volumn 37, Issue 7, 2014, Pages 1938-1943

  Ceriello, Antonio ^a   Novials, Anna ^a   Canivell, Silvia ^a   La Sala, Lucia ^a   Pujadas, Gemma ^a   Esposito, Katherine ^b   Testa, Roberto ^c   Bucciarelli, Loredana ^d   Rondinelli, Maurizio ^d   Genovese, Stefano ^d  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c INRCA   (Italy)

^d IRCCS MULTIMEDICA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; 8 ISOPROSTAGLANDIN F2 ALPHA; GLUCAGON LIKE PEPTIDE 1; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; 8-EPI-PROSTAGLANDIN F2ALPHA; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; PROSTAGLANDIN F2 ALPHA; VASODILATOR AGENT;

ADULT; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FLOW RATE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PROTEIN DETERMINATION; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; VASODILATATION; ANALOGS AND DERIVATIVES; BLOOD; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; HYPERINSULINISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; DIABETES MELLITUS, TYPE 2; DINOPROST; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN; INTERLEUKIN-6; MALE; MIDDLE AGED; OXIDATIVE STRESS; VASODILATOR AGENTS;

EID: 84903511924     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2618     Document Type: Article

References (20)

1. Dandona P, Chaudhuri A, Ghanim H, Mohanty P. Insulin as an anti-inflammatory and antiatherogenic modulator. J Am Coll Cardiol 2009;53(Suppl.):S14-S20
2. Dandona P, Aljada A,Mohanty P, et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an antiinflammatory effect? J Clin Endocrinol Metab 2001;86:3257-3265 (Pubitemid 32674120)
3. Monnier L, Colette C,Mas E, et al. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia 2010;53:562-571
4. Mudaliar S, Henry RR. Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. Am J Med 2010;123(Suppl.):S19-S27
5. Nyström T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. AmJ Physiol Endocrinol Metab 2004;287:E1209-E1215 (Pubitemid 39491964)
6. Ceriello A, Esposito K, Testa R, Bonfigli AR, Marra M, Giugliano D. The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagon-like peptide 1 in diabetes. Diabetes Care 2011;34:697-702
7. Ceriello A, Novials A, Ortega E, et al. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care 2013;36:2346-2350
8. Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Silljé HH. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol 2010;30:1407-1414
9. van der Klauw MM, Wolffenbuttel BH. The combination of insulin and GLP-1 analogues in the treatment of type 2 diabetes. Neth J Med 2012;70:436-443
10. Tesauro M, Schinzari F, Adamo A, et al. Effects of GLP-1 on forearm vasodilator function and glucose disposal during hyperinsulinemia in the metabolic syndrome. Diabetes Care 2013; 36:683-689
11. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223 (Pubitemid 9249478)
12. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91:301-307 (Pubitemid 23037285)
13. Ceriello A, Mercuri F, Quagliaro L, et al. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 2001; 44:834-838 (Pubitemid 32642455)
14. Okerson T, Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther 2012;30:e146-e155
15. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010;107:1058-1070
16. Rashid K, Sinha K, Sil PC. An update on oxidative stress-mediated organ pathophysiology. Food Chem Toxicol 2013;62:584-600
17. Annamalai AK,Webb A, Kandasamy N, et al. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J Clin Endocrinol Metab 2013;98:1040-1050
18. Marfella R, Verrazzo G, Acampora R, et al. Glutathione reverses systemic hemodynamic changes induced by acute hyperglycemia in healthy subjects. Am J Physiol 1995;268:E1167-E1173
19. Marfella R, Nappo F, De Angelis L, Siniscalchi M, Rossi F, Giugliano D. The effect of acute hyperglycaemia on QTc duration in healthy man. Diabetologia 2000;43:571-575 (Pubitemid 30322074)
20. Esposito K, Nappo F,Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002;106:2067-2072 (Pubitemid 35192812)